Esophageal cancer (EC) is one of the most lethal cancers in the world, and its morbidity and
mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy …

Vascular endothelial growth factor (VEGF) represents a growth factor with important pro-
angiogenic activity, having a mitogenic and an anti-apoptotic effect on endothelial cells …

Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein
tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis …

Background Almost half of people with esophageal or gastroesophageal junction cancer
have metastatic disease at the time of diagnosis. Chemotherapy and targeted therapies are …

Simple Summary Gastric cancer is the fifth most common tumor worldwide. In the past
couple of decades, there have been many advancements toward earlier detection and better …

Background Targeted therapy with tyrosine kinase inhibitors with anti-vascular endothelial
growth factor activity improves survival of cancer patients. Cardiovascular complications are …

Since bevacizumab was first approved by the US Food and Drug Administration as an anti-
angiogenic therapy in 2004, angiogenesis-targeted therapy has been developed for various …

Angiogenesis is one of the hallmarks of cancer. Several studies have shown that vascular
endothelium growth factor (VEGF) plays a leading role in angiogenesis progression …

Simple Summary Gastric cancer is characterized by poor survival rates despite surgery and
chemotherapy. Current research focuses on biomarkers to improve diagnosis and …

Purpose: No antiangiogenic treatment is yet approved for extrapancreatic neuroendocrine
tumors (NET). Surufatinib (HMPL-012, previously named sulfatinib) is a small-molecule …